Efficacy, Safety, and Pharmacokinetics of Teclistamab in Chinese Patients with Relapsed/refractory Multiple Myeloma from the China Cohort of MajesTEC-1.
CANCER（2025）
Key words
bispecific antibody (BsAb),relapsed/refractory multiple myeloma (RRMM),teclistamab,triple-class exposed (TCE)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined